May
Centocor pulls cancer drug application
Centocor has decided not to pursue US approval of ovarian cancer drug trabectedin, with the FDA stating that the company would need to conduct an additional phase III clinical trial before approval could be granted
03 May 2011
FDA advisors back Vertex HCV drug
An advisory committee to the US Food and Drug Administration has unanimously backed Vertex Pharmaceuticals' investigational new therapy for hepatitis C
03 May 2011
Teva to acquire Cephalon for $6.8bn
The world's largest generic drug maker, Teva Pharmaceutical, has entered into an agreement to acquire global biopharmaceutical company Cephalon for $6.8bn
03 May 2011
Pfizer reports Q1 revenue of $16.5bn
Pfizer has announced Q1 2011 revenue of $16.5bn, consistent with the same period in 2010
03 May 2011
Carsten Edwards joins Ogilvy Healthworld
Carsten Edwards will be joining Ogilvy Healthworld Market Access as managing partner in June 2011
03 May 2011
Mylan Q1 profit increases
Mylan has reported a major increase in first-quarter profit, due mainly to robust sales in North America
04 May 2011
Lilly/Boehringer diabetes drug approved
The US Food and Drug Administration has granted marketing approval to a type 2 diabetes drug developed through a partnership between Lilly and Boehringer Ingelheim
04 May 2011
Onyx reports Q1 loss of $14.2m
Onyx Pharmaceuticals has reported a non-GAAP net loss of $14.2m for the first quarter 2011 compared with a non-GAAP net loss of $1.5m for the same period last year
04 May 2011
Almirall/ Nycomed COPD co-branding deal
Almirall and Nycomed have entered into a co-branding agreement for the commercialisation of roflumilast, a once-daily tablet for patients with chronic obstructive pulmonary disease, in Spain
05 May 2011
S-A agrees malaria research project
Sanofi-aventis and Medicines for Malaria Venture (MMV) are to work together on Orthology Malaria – a project to research malaria treatments
05 May 2011